FDA 483 - Jorge Amaya, MD - November 17, 2021

An FDA inspection of Jorge Amaya, MD, a clinical investigator in Miami, FL, revealed one significant observation. The firm failed to conduct an investigation in accordance with the signed statement of investigator and investigational plan, specifically regarding a subject who received prohibited treatment without completing required washouts. This indicates a serious deviation from clinical trial protocol.